Biology and Institute of Molecular Biology
University of Oregon
Eugene, OR, USA
Focus: cell-fate specification, development, cell biology, cytoskeletal function
CGC lab code: EU
CGC allele code: or
Year founded: 1992
When did you join the field?
What brought you to the field?
I interviewed for a postdoc with Marty Chalfie while still in grad school at UCSF, and his infectious enthusiasm convinced me I wanted to work with C. elegans. But I had already been lured to the early embryo by Jim Priess’ 1987 Cell papers on GLP-1/Notch signaling and the induction of the anterior pharynx. So after visiting Marty’s lab I wrote Jim Priess asking him if I could visit his lab to explore postdoc possibilities. Jim never replied (I later learned he never checks his mail, as in USPS mail), and so I called him on the phone, and by the fall of 1989 arrived in his lab to start my postdoc.
My first project was to follow the lineage of a hypodermal precursor (I think it was ABplap), and determine if a cell interaction influenced its fate. I spent many hours drawing embryos and this cell lineage as it underwent its divisions, and eventually was able to follow the lineage to its terminal divisions. I was very pleased to be doing some lineaging; I would brag to my former PhD classmates how the only solution I was using in my postdoc was agar and water. However, all I got out of this project was a lot of pretty drawings. In parallel, we had begun EMS screens for embryonic lethal mutants and found a skn-1 allele, zu67. I switched to working on skn-1 (a.k.a. skinhead) and spent most of the rest of my postdoc focusing on that project, which was very satisfying. I finally knew I had found a niche in life and wanted to stay in science. Working in lab with Jim was, and remains, such a wonderful privilege.
What is your specific research focus?
A strength and a weakness of my research is that I have never really had much of a specific focus. Most of the research projects in my lab have originated from the identification of embryonic-lethal mutants with interesting defects in early embryogenesis, initially with respect to cell fate patterning but subsequently focused more on cytoskeletal function and early embryonic cell division. As a result, our focus has shifted from time to time as we found mutants that proved to have defects in a range of different genetic pathways. Some of our most satisfying contributions include work on Wnt signaling in the early embryo, ubiqutin-mediated proteolysis/CUL-3 function in the early embryo, mitotic spindle assembly, cytokinesis, and most recently oocyte meiotic spindle assembly. We also have recently begun to apply Illumina-based genome-wide SNP mapping and whole genome sequencing to more rapidly identify the affected genes in large numbers of temperature-sensitive, embryonic-lethal mutants, focusing on those with penetrant defects in embryonic morphogenesis (a collaboration with Zhirong Bao at Memorial Sloan Kettering Cancer Center). Our lack of a focus has been a weakness in that my lab has never had an identity with respect to a specific biological process as a research focus, and that has probably made it more difficult to recruit graduate students and postdocs, although I have been very satisfied with the number and quality of people who have joined my lab over the years. Our lack of focus has been a strength in that my lab has explored a variety of fascinating pathways and processes, and I like something Sandy Johnson at UCSF once told me when I was finishing my PhD–that one of the best things you can bring to a field is naivite. While there are limits to that perspective, I have always felt like there also is some truth to it; that one enters into a new field without having a lifetime of dogma potentially clouding one’s perspective.
Do you have a favorite experiment, humorous story, or meeting anecdote you would like to share?
I could go on forever here! Welcome to my blog.
Favorite experiment: showing that Wnt signaling influences the orientation of the mitotic spindle in EMS independently of gene expression, suggesting that Wnt signaling can directly target the cytoskeleton (rather than first influencing gene expression in the nucleus via its influence on beta-catenin and TCF transcription factors). I felt like this was a novel contribution to the field of Wnt signaling and it began a shift in our focus from cell fate specification to cytoskeletal function and cell biology. Ann Schlesinger was the second PhD student to join my lab and this work was the primary focus of her dissertation work.
Humorous story/meeting anecdote: It amazes me how even today, some 25 years later, people still regularly ask me about the big food fight at the worm meeting in Madison, in what must have been 1991, when I was still a postdoc in Jim Priess lab. That was a very special food fight (I was a veteran of food fights from Cold Spring Harbor RNA Tumor Virus meetings during my PhD work in the Harold Varmus lab at UCSF). However, I do remain disappointed that my efforts to lead a charge on the many big name faculty watching from the top of the steps was unsuccessful. And Judith, I am really sorry about that cleaning bill (very odd that the banquet room had red velvet wallpaper). I understand it was an immature and irresponsible moment in my life. But that cream puff pie was a really dangerous choice for dessert, and it sure was fun to take advantage of it (and spare people from actually having to eat that stuff!). And after the food fight was over, I will always be grateful to John Sulston, Phil Anderson and Alan Coulson, who effusively congratulated me on my effort while I was in the bathroom hiding from Judith Kimble.
What is your lab’s biggest contribution to the field?
I would have to say that our biggest contribution (not counting the Madison food fight) was our discovery that MEL-26 is an adaptor protein that recruits MEI-1/katanin to a CUL-3-based E3 ligase, targeting MEI-1 for degradation by the proteasome after the completion of oocyte meiosis I and II. This work was done by two graduate students in my lab, Thimo Kurz and John Willis, in a very productive collaboration with Lionel Pintard when he was a postdoc with Mathias Peter and Pierre Gonczy. This discovery is particularly significant in that it established that proteins with a Cullin-binding BTB domain and another protein-protein interaction domain function as adaptors for Cullin 3-based E3 ligases (i.e. MEL-26 was the founding member of this CUL-3 adaptor gene family). As there are over 100 such proteins in humans, and over 100 in , this finding pointed to a function for many different genes that had previously been of unknown function. Hard to beat that for satisfaction when it comes to gene discovery as a classical geneticist.
What is the biggest “rabbit hole” your lab ever fell into?
My lab identified a recessive, embryonic-lethal mutation in bmk-1, which encodes the ortholog of the Eg5 kinesin that plays an essential role in promoting mitotic spindle bipolarity in most animal phyla. This was surprising, because two large deletion alleles of bmk-1 are homozygous viable, and papers had been published concluding that bmk-1 is not essential in C. elegans (with the only detectable requirement being to modestly decrease the rate of P0 spindle elongation during the first embryonic mitotic cell division). However, our bmk-1(or645ts) allele was 100% embryonic-lethal at 25 degrees C, with monopolar oocyte meiotic spindles, consistent with its known role in promoting spindle bipolarity during mitosis in vertebrates. I convinced myself that the two deletion alleles were not null and we had finally discovered the essential function for bmk-1 in C. elegans. We therefore devoted a great deal of effort toward further characterizing this mutant phenotype. However, one day Rene Medema, at the Netherlands Cancer Institute, emailed me asking if they might use our bmk-1(or645ts) allele in some sort of suppressor or enhancer screen. Rene works on kinesins, mostly in vertebrates, but also was pursuing some work in C. elegans. When I explained how we believed our allele was a loss of function mutation that had revealed the essential requirements for this gene, he asked me if I had considered the possibility that it might be a gain of function allele. I immediately began to experience a sinking sensation in my gut and admitted I had not. I at least realized we could test that idea by using RNAi to knock down bmk-1 in our or645ts mutant background. We did that, and embryonic lethality at 25 degrees C went from 100% to almost nothing! This showed that or645ts is in fact a fully recessive gain-of-function mutation with some sort of neomorphic effect. Another way of saying this is that or645ts is a dosage-sensitive gain-of-function mutation, which makes it a little easier to wrap my head around this conclusion. We published this as supplemental data in a Molecular Biology of the Cell paper that focused on loss-of-function mutations in other genes required for oocyte meiotic spindle assembly. Two different PhD students in my lab had invested a substantial amount of effort to this project, and it was mostly all for naught. We now use RNAi to knock down gene function in recessive TS lethal mutants we study, if their mutant phenotype is different from that reported in RNAi screens, to test for this possibility (we've run into one other somewhat similar case). I think the lesson here is that you do enough genetics in your life, you'll eventually run into some weird shit.
|Aleesa J Schlientz||Phd||2015|
|Danielle R. Hamill||Postdoc||2007||2011|
|Jennifer B. Phillips||Phd||1999||2014|
|John Joseph Yochem||Research_staff||2009||2011|
|Christopher J Thorpe||Phd||1993||1998|
|John H Willis||Phd||1999||2004|
|Morgan Ben Goulding||Postdoc||2001||2008|
|Julie C. Canman||Postdoc||2003||2006|
|Sean M. O’Rourke||Postdoc||2002||2007|
|Meredith H Price||Masters||2005||2009|
|Thimo K. Kurz||Phd||1998||2003|
|Luke A Carter||Research_staff||2008||2010|
Articles submitted to the Worm Breeder's Gazette should not be cited in bibliographies. Material contained here should be treated as personal communication and cited as such only with the consent of the author.